Certican derives Successful Result

.

Certican derives Successful Result

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

In addition, it has been said that the project is considered to be the biggest project that has been taken out by the company with regard to liver transplant. It has been found that the drug is quite effective in improving renal function among patients.

The data about the same was revealed at the meeting of American Association for the Study of Liver Diseases (AASLD), which is in its 63rd year. The drug, which has already received approval from European health authorities, is likely to get approval from the US health regulators Food and Drug Administration by the end of 2012.

"These results showed that treatment with Certican with reduced tacrolimus led to a clinically relevant retention of renal function compared to standard tacrolimus, with no compromise in rejection", said John Fung, who is positioned as director at Transplantation Center. It is expected that the drug is able to provide benefit to adults suffering from liver problem.


Latest News

Avago Technologies Ltd Acquiring Broadcom Corp. The Deal may Put Qualcomm Under
Seven Year Long Lawsuit against Cephalon Settled with Teva Pharmaceuticals Payin
Exxon CEO Rebuffs Criticism of Not Doing Enough to Cut Carbon Emissions
McDonald’s Toasting Buns for Longer to get Better Taste
SWIFT says, Yuan is presently the Most-Used Currency in Asia for Payments to Chi
U.S. Dollar gets a Lift Strengthening Hopes of Raise in Interest Rate
Hackers Steal Tax Information of 100,000 American Taxpayers from IRS site
Charter Communications is Acquiring Time Warner Cable for about $56 Billion
Greece’s Interior Minister Says Greece will not be Able to Repay Debt Next Month
Nikos Voutsis, Greece’s Interior Minister
Rig Count in U.S Slows, Oil Trades Close to $60
Third Annual ‘March against Monsanto’ held on Saturday